iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Significant Transactions (Tables)

Significant Transactions (Tables)

12 Months Ended

Jun. 30, 2023

Summary of Purchase Price Allocation of Asset Acquisition


Preferred stock		$	1,760,000
Intangible assets			4,300,000
Prepaid expenses			1,440,000
		$	7,500,000

RubrYc Therapeutics, Inc. [Member] | Asset Purchase Agreement [Member]

Summary of Purchase Price Allocation of Asset Acquisition


Intangible assets		$	1,228,000
Fixed assets			114,000
		$	1,342,000